# Contrast Media: Pharmacology, Reactions, and Nephrotoxicity

## Iodinated Contrast Media

### Classification

Iodinated contrast agents are classified by their osmolality relative to blood. High-osmolality contrast media (HOCM), such as diatrizoate (Hypaque), are ionic monomers with osmolality around 1,500 to 2,000 mOsm/kg. They are largely obsolete for intravascular use because of higher adverse reaction rates. Low-osmolality contrast media (LOCM), with osmolality in the range of 600 to 800 mOsm/kg, are the most commonly used class today. The non-ionic monomers in this group include iohexol (Omnipaque), iopamidol (Isovue), ioversol (Optiray), and iomeprol (Iomeron). Ioxaglate (Hexabrix) is an ionic dimer that also falls in this category. Iso-osmolality contrast media (IOCM), with osmolality around 290 mOsm/kg (equal to blood), are represented by the non-ionic dimer iodixanol (Visipaque). Current standard of care uses LOCM or IOCM for all intravascular contrast injections.

| Category | Osmolality (mOsm/kg) | Type | Examples | Current Use |
|----------|----------------------|------|----------|-------------|
| HOCM | 1,500-2,000 | Ionic monomer | Diatrizoate (Hypaque) | Largely obsolete for IV use |
| LOCM | 600-800 | Non-ionic monomer | Iohexol (Omnipaque), Iopamidol (Isovue), Ioversol (Optiray) | Standard of care |
| LOCM | 600 | Ionic dimer | Ioxaglate (Hexabrix) | Limited use |
| IOCM | ~290 (iso-osmolar) | Non-ionic dimer | Iodixanol (Visipaque) | Standard of care |

### Pharmacokinetics

Iodinated contrast agents distribute in the extracellular space (both intravascular and interstitial compartments). They have no significant protein binding and are not metabolized. Excretion is almost entirely by glomerular filtration, with more than 95% eliminated within 24 hours in patients with normal renal function. In patients with renal failure, hepatobiliary excretion increases through a compensatory mechanism called vicarious excretion, which can opacify the gallbladder on delayed imaging.

### Contrast Dosing and Administration

Typical intravenous doses range from 1 to 2 mL/kg of a 300 to 370 mgI/mL concentration. Flow rates vary by application: 2 to 5 mL/s for CT angiography and 1 to 3 mL/s for routine enhanced CT. Bolus tracking or test bolus techniques are used to optimize arterial phase timing. A saline flush of 20 to 50 mL after contrast injection improves contrast bolus geometry and can reduce the total contrast dose needed.

## Adverse Reactions to Iodinated Contrast

### Classification of Reactions

Adverse reactions fall into two categories. Allergic-like (anaphylactoid or hypersensitivity) reactions are not true IgE-mediated anaphylaxis in most cases; they involve direct activation of mast cells and basophils. These reactions are not dose-dependent, cannot be predicted by "allergy testing" or a test dose, and the strongest risk factor for recurrence is a prior allergic-like reaction. Physiologic (chemotoxic) reactions are dose-dependent effects related to osmolality and chemotoxicity, including nausea, vomiting, vasovagal reactions, cardiac arrhythmias, seizures, and pulmonary edema.

### Severity Grading

Mild reactions include limited urticaria (a few scattered hives), pruritus, nasal congestion, sneezing, mild nausea, and limited cutaneous edema. Most resolve spontaneously and can be managed with observation and diphenhydramine for urticaria. Moderate reactions include diffuse urticaria, facial edema without dyspnea, mild bronchospasm with wheezing, mild hypotension responsive to positioning, and tachycardia or bradycardia. These require active treatment but may resolve without progression. Severe reactions include laryngeal edema with stridor and airway compromise, severe bronchospasm with significant hypoxia, anaphylaxis with cardiovascular collapse, seizures, and cardiopulmonary arrest. Epinephrine is the first-line treatment for anaphylaxis, and the code team should be activated if needed.

| Severity | Symptoms | Management |
|----------|----------|------------|
| Mild | Scattered urticaria, pruritus, nasal congestion, sneezing, mild nausea | Observation; diphenhydramine 25-50 mg IV for urticaria |
| Moderate | Diffuse urticaria, facial edema, mild bronchospasm, mild hypotension | Diphenhydramine, beta-agonist inhaler, consider epinephrine IM |
| Severe | Laryngeal edema, severe bronchospasm, anaphylaxis, cardiovascular collapse, seizures | Epinephrine IM 0.3 mg (1:1,000) first-line; IV fluids; O₂; code team |

### Acute Reaction Treatment (ACR Manual on Contrast Media)

For urticaria, mild scattered hives are managed with observation and diphenhydramine 25 to 50 mg IV. If hives are diffuse or progressing, epinephrine should be considered. For bronchospasm, a beta-2 agonist inhaler (albuterol, 2 puffs) and supplemental oxygen are first-line, with epinephrine IM (0.3 mg of 1:1,000 solution) reserved for severe or refractory cases. For laryngeal edema, epinephrine IM (0.3 mg of 1:1,000) is the first-line treatment, supplemental oxygen should be provided, and preparation for potential intubation is essential. For hypotension with tachycardia (anaphylactoid shock), epinephrine IM, aggressive IV fluid resuscitation with normal saline, and leg elevation are all indicated, with epinephrine repeated every 5 to 15 minutes as needed. For vasovagal reactions (hypotension with bradycardia), leg elevation and IV fluids are usually sufficient, with atropine 0.6 to 1.0 mg IV administered for symptomatic bradycardia and repeated as needed to a maximum of 3 mg.

### Risk Factors for Allergic-Like Reactions

The strongest predictor of a contrast reaction is a prior reaction to contrast media, which increases risk approximately fivefold with LOCM. Asthma, especially when poorly controlled, multiple or severe allergies, and mastocytosis or mast cell disorders are also risk factors. It is important to note that shellfish allergy is not a specific risk factor, despite a persistent clinical myth based on the shared iodine content between shellfish and contrast agents. Iodine is a ubiquitous element and is not itself an allergen.

### Premedication Protocols

Premedication is indicated for patients with a prior allergic-like reaction to contrast media. The ACR-recommended regimen is prednisone 50 mg orally at 13 hours, 7 hours, and 1 hour before injection, plus diphenhydramine 50 mg (IV, IM, or oral) 1 hour before. An alternative is methylprednisolone 32 mg orally at 12 hours and 2 hours before, plus diphenhydramine. For accelerated or emergency premedication, methylprednisolone 40 mg IV or hydrocortisone 200 mg IV is given every 4 hours until contrast administration, plus diphenhydramine 50 mg IV 1 hour before. However, accelerated protocols may be less effective because corticosteroids require at minimum 4 to 6 hours to achieve their protective effect. A different contrast agent class than the one that caused the prior reaction should be used. Even with premedication, breakthrough reactions occur in an estimated 1 to 2% of cases.

### Delayed Reactions

Delayed reactions occur 1 hour to 7 days after contrast administration. The most common presentation is skin reactions, including maculopapular rash and urticaria. Risk factors include a prior delayed reaction, IL-2 therapy, and use of non-ionic dimers such as iodixanol. Most delayed reactions are self-limited and managed symptomatically.

## Contrast-Induced Nephropathy (Post-Contrast AKI)

### Traditional Concept

Contrast-induced nephropathy has traditionally been defined as a rise in serum creatinine of 0.3 mg/dL or more, or 50% or more from baseline, within 48 to 72 hours of intravascular contrast administration. Historical incidence was reported at 5 to 15%, depending on the study population and definition used.

### Evolving Understanding

The preferred term is now post-contrast acute kidney injury (PC-AKI), which distinguishes the observed association from proven causation. Multiple large propensity-matched studies comparing contrast-enhanced CT to non-contrast CT have shown no significant difference in AKI rates between the two groups when eGFR is 30 mL/min or above. This has led to questioning whether contrast itself causes nephropathy or whether the observed kidney injury is merely an association with underlying comorbidities such as dehydration, hypotension, and nephrotoxic medications. The risk appears real primarily in patients with eGFR below 30 mL/min (severe chronic kidney disease) and in those receiving intra-arterial contrast with first-pass renal exposure, such as during aortography with renal artery catheterization.

### Current ACR Recommendations (2024 Manual)

For patients with eGFR of 30 mL/min or above, there is no increased risk of PC-AKI with IV iodinated contrast, and no special precautions are needed. For patients with eGFR below 30 who are not on dialysis, there is a potential risk; risks and benefits should be weighed, and IV hydration with normal saline should be provided if contrast is administered. For dialysis patients, contrast will be removed by dialysis, and the timing of the dialysis session does not need to be altered; the primary concern is volume overload rather than nephrotoxicity. In emergent situations, a clinically indicated contrast-enhanced study should never be delayed for creatinine or eGFR testing, because the risk of missing a diagnosis outweighs the risk of PC-AKI. IV hydration with normal saline (1 mL/kg/hr for 6 to 12 hours before and after) is the most effective preventive measure when indicated. Metformin should be discontinued only if eGFR is below 30 or if PC-AKI actually develops; it no longer needs to be routinely held for patients with normal renal function.

| eGFR (mL/min/1.73m²) | Risk of PC-AKI | Precautions | Metformin |
|----------------------|----------------|-------------|-----------|
| ≥30 | No significant increased risk | Standard contrast administration | Continue; no need to hold |
| 15-29 (not on dialysis) | Potential risk | IV hydration with NS; weigh risk vs benefit | Discontinue |
| <15 or dialysis | Volume overload concern | Contrast cleared by dialysis; timing unchanged | Discontinue |
| Emergency (any eGFR) | Do not delay study | Proceed; benefit outweighs risk | Assess after study |

## Gadolinium-Based Contrast Agents

### Classification

As covered in more detail in the MRI safety topic, macrocyclic agents (Gadavist, Dotarem, ProHance) are preferred over linear agents due to their greater stability. The NSF risk is essentially zero with Group III agents at standard doses when eGFR is 30 or above. eGFR should be screened in at-risk populations before administration.

### Iodinated vs. Gadolinium Contrast Comparison

Iodinated agents have higher overall reaction rates (approximately 0.5 to 3% for LOCM) compared to GBCAs (approximately 0.07 to 0.77%), though both rates are low. There is no cross-reactivity between the two classes because they are chemically distinct. A prior reaction to iodinated contrast does not predict a GBCA reaction, and vice versa.

## Contrast Extravasation

### Risk Factors

Extravasation, the leakage of contrast from the vein into surrounding tissues, is more common with fragile veins (in elderly patients, those receiving chemotherapy, or those with multiple prior IV accesses), high flow rates from power injectors, indwelling IV catheters that have been in place for more than 24 hours, and extremities with compromised venous or lymphatic drainage.

### Management

Small-volume extravasations (less than 10 mL) are managed with observation, elevation, and ice; nearly all resolve without sequelae. Large-volume or symptomatic extravasations require clinical assessment for signs of compartment syndrome, including pain out of proportion to findings, a tense compartment, and diminished pulses or sensation. Compartment syndrome is rare but requires emergent surgical consultation. Non-ionic LOCM causes less tissue damage than HOCM if extravasated.

<image>A flowchart for the management of acute contrast reactions in the radiology department. The chart begins with the classification of the reaction as either allergic-like or physiologic. For allergic-like reactions, three severity branches are shown: mild (urticaria/pruritus -- treat with observation plus diphenhydramine), moderate (diffuse urticaria, facial edema, mild bronchospasm -- treat with diphenhydramine, beta-agonist inhaler, and consider epinephrine IM), and severe (anaphylaxis, laryngeal edema, severe bronchospasm, cardiovascular collapse -- treat with epinephrine IM 0.3 mg first-line, IV fluids, oxygen, and call code team). For physiologic reactions, branches show vasovagal (bradycardia plus hypotension -- treat with leg elevation, IV fluids, atropine if needed) and other reactions (nausea/vomiting, seizure -- treat symptomatically). All branches lead to a documentation and reporting box.</image>

<image>A risk stratification diagram for post-contrast acute kidney injury. A horizontal bar represents the eGFR spectrum from 0 to greater than 60 mL/min. Three color-coded zones are shown: green (eGFR >= 30, label "no significant increased risk of PC-AKI; standard contrast administration"), yellow (eGFR 15-29, label "potential risk; hydrate with IV normal saline; weigh risk vs benefit; consider alternative imaging"), and red (eGFR less than 15 or dialysis, label "risk of volume overload; contrast will be cleared by dialysis; timing of dialysis session does not need to change"). A callout box emphasizes that emergent contrast-enhanced studies should never be delayed for creatinine testing regardless of renal function status.</image>

<image>A comparison table of iodinated contrast media categories. Three columns show High-Osmolality (HOCM), Low-Osmolality (LOCM), and Iso-Osmolality (IOCM) agents. Each column lists: chemical structure type (ionic monomer, non-ionic monomer, non-ionic dimer), osmolality range, example agent names, and relative adverse reaction rates depicted as a descending bar graph from HOCM (highest) to IOCM (lowest). A note at the bottom states that LOCM and IOCM are the current standard of care for all intravascular contrast injections.</image>

## Clinical Pearls

Shellfish allergy is not a risk factor for iodinated contrast reactions. This is a persistent myth, and iodine is a ubiquitous element, not an allergen. Epinephrine IM (1:1,000, 0.3 mg) is the first-line drug for severe allergic-like contrast reactions including anaphylaxis, laryngeal edema, and severe bronchospasm, and its administration should not be delayed. Premedication with corticosteroids requires at least 4 to 6 hours to be effective; a single dose given immediately before contrast provides essentially no protection. Current evidence strongly suggests that IV iodinated contrast does not cause clinically significant nephropathy in patients with eGFR of 30 or above, and the traditional concept of "contrast-induced nephropathy" is being fundamentally reassessed. An emergent contrast-enhanced study should never be delayed to check renal function, because the risk of missing a life-threatening diagnosis far outweighs the risk of contrast-related kidney injury. Metformin does not need to be held before contrast in patients with normal renal function (eGFR of 30 or above). Every radiology department should have a contrast reaction kit stocked with epinephrine, diphenhydramine, atropine, albuterol, IV fluids, and oxygen, and every resident should know its location and contents.

## References

- ACR Manual on Contrast Media, Version 2024 (American College of Radiology Committee on Drugs and Contrast Media)
- Davenport MS, et al. "Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation." *Radiology*, 2020
- McDonald RJ, et al. "Intravenous Contrast Material-Induced Nephropathy: Causal or Coincident Phenomenon?" *Radiology*, 2013
- Katayama H, et al. "Adverse Reactions to Ionic and Nonionic Contrast Media." *Radiology*, 1990
- Beckett KR, et al. "Safe Use of Contrast Media: What the Radiologist Needs to Know." *RadioGraphics*, 2015